CELC Key Statistics, Chart & Performance
The current stock price of CELC is 105.63 USD. In the past month the price increased by 42.36%. In the past year, price increased by 703.27%.
CELC Latest News, Press Relases and Analysis
CELC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About CELC
Company Profile
Celcuity, Inc. operates as a cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 87 full-time employees. The company went IPO on 2017-09-20. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Company Info
CELCUITY INC
16305 36th Ave N Ste 100
Minneapolis MINNESOTA 55446 US
CEO: Brian F. Sullivan
Employees: 87
Phone: 17633920767
CELCUITY INC / CELC FAQ
What does CELCUITY INC do?
Celcuity, Inc. operates as a cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 87 full-time employees. The company went IPO on 2017-09-20. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
What is the current price of CELC stock?
The current stock price of CELC is 105.63 USD. The price decreased by -0.23% in the last trading session.
What is the dividend status of CELCUITY INC?
CELC does not pay a dividend.
What is the ChartMill rating of CELCUITY INC stock?
CELC has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for CELC stock?
15 analysts have analysed CELC and the average price target is 97.67 USD. This implies a price decrease of -7.54% is expected in the next year compared to the current price of 105.63.
What is the market capitalization of CELC stock?
CELCUITY INC (CELC) has a market capitalization of 4.89B USD. This makes CELC a Mid Cap stock.
Can you provide the upcoming earnings date for CELCUITY INC?
CELCUITY INC (CELC) will report earnings on 2026-03-30, after the market close.
CELC Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CELC. When comparing the yearly performance of all stocks, CELC is one of the better performing stocks in the market, outperforming 99.62% of all stocks.
CELC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CELC. CELC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CELC Financial Highlights
Over the last trailing twelve months CELC reported a non-GAAP Earnings per Share(EPS) of -3.67. The EPS decreased by -40.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -81.11% | ||
| ROE | -335.59% | ||
| Debt/Equity | 2.24 |
CELC Forecast & Estimates
15 analysts have analysed CELC and the average price target is 97.67 USD. This implies a price decrease of -7.54% is expected in the next year compared to the current price of 105.63.